Literature DB >> 11579091

Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway.

G S Bogatkevich1, E Tourkina, R M Silver, A Ludwicka-Bradley.   

Abstract

Myofibroblasts are ultrastructurally and metabolically distinctive fibroblasts that express smooth muscle (SM)-alpha actin and are associated with various fibrotic lesions. The present study was undertaken to investigate the myofibroblast phenotype that appears after activation of normal lung fibroblasts by thrombin. We demonstrate that thrombin induces smooth muscle-alpha actin expression and rapid collagen gel contraction by normal lung fibroblasts via the proteolytically activated receptor-1 and independent of transforming growth factor-beta pathway. Using antisense oligonucleotides we demonstrate that a decreased level of PKCepsilon abolishes SM-alpha actin expression and collagen gel contraction induced by thrombin in normal lung fibroblasts. Inhibition of PKCepsilon translocation also abolishes thrombin-induced collagen gel contraction, SM-alpha actin increase, and its organization by normal lung fibroblasts, suggesting that activation of PKCepsilon is required for these effects. In normal lung fibroblasts PKCepsilon binds to SM-alpha actin after thrombin treatment, but in activated fibroblasts derived from scleroderma lung they associate even in untreated cells. This suggests that SM-alpha actin may serve as a substrate for PKCepsilon in lung fibroblasts when activated by thrombin. We propose that thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via a PKC-dependent pathway. Thrombin-induced differentiation of normal lung fibroblasts to a myofibroblast phenotype resembles the phenotype observed in scleroderma lung fibroblasts. Therefore, we conclude that chronic exposure to thrombin after microvascular injury leads to activation of normal lung fibroblasts and to the appearance of a myofibroblast phenotype in vivo. Our study provides novel, compelling evidence that thrombin is an important mediator of the interstitial lung fibrosis associated with scleroderma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579091     DOI: 10.1074/jbc.M106441200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  A novel in vitro dermal wound-healing model incorporating a response to mechanical wounding and repopulation of a fibrin provisional matrix.

Authors:  R O'Leary; E J Wood
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 May-Jun       Impact factor: 2.416

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  PKCalpha mediates CCL18-stimulated collagen production in pulmonary fibroblasts.

Authors:  Irina G Luzina; Kendrick Highsmith; Kerill Pochetuhen; Natalia Nacu; Jaladanki N Rao; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-06       Impact factor: 6.914

Review 4.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

5.  Induction of the myofibroblast phenotype following elastolytic injury to mouse lung.

Authors:  David C Rishikof; Edgar C Lucey; Ping-Ping Kuang; Gordon L Snider; Ronald H Goldstein
Journal:  Histochem Cell Biol       Date:  2005-11-19       Impact factor: 4.304

6.  Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Richard M Silver
Journal:  Arthritis Rheum       Date:  2009-11

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

Review 8.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

9.  Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation.

Authors:  Keren Borensztajn; Jurriën Stiekema; Sebastiaan Nijmeijer; Pieter H Reitsma; Maikel P Peppelenbosch; C Arnold Spek
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

10.  Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2009-12-03       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.